Immunotherapy Advances in RRMM: An Educational Journey

To participate in this activity, please start here:

Multiple myeloma has become the most common hematologic malignancy in the United States adult population with over 120,000 people living with the disease. Despite new and more effective treatments, multiple myeloma, unfortunately, remains largely incurable with relapse and disease progression still common.

Dr. Ola Landgren Chief of the Myeloma Service at Memorial Sloan-Kettering Cancer Center and professor of medicine at Cornell Medical College discusses advances in the field of immunotherapy for relapsed refractory multiple myeloma (RRMM). He discusses different treatment modalities and their unique strengths and limitations which have shown high antimyeloma activity that may address a critical unmet need in heavily pretreated and refractory patients. Dr. Landgren indicates that future studies will help identify optimal combinations and sequencing of different immunotherapies.

Course Credit:

1.00 AANP Contact Hour
1.00 AMA PRA Category 1 CreditTM
1.00 ANCC Contact Hour
1.00 CA-BRN Contact Hour

Dates:

Opens: 2020-07-31
Closes: 2021-07-30

Target Audience:

This activity is intended for hematologists-oncologists, nurse practitioners, nurses, and other healthcare professionals.

This activity is supported by an independent educational grant from bluebird bio, Legend Biotech and Sanofi Genzyme.
  • C. Ola Landgren, MD, PhD

    Chief, Myeloma Service
    Memorial Sloan-Kettering Cancer Center (MSKCC)
    New York, New York

Learning Objectives

  • Assess the factors that determine the choice of therapy for patients with relapsed/refractory multiple myeloma (RRMM), including disease heterogeneity, risk stratification, prior therapies, patient characteristics and comorbidities, performance status, and treatment goals.
  • Compare and contrast the current and emerging immunotherapy approaches for patients with RRMM, including the evolving role of immunotherapies targeting BCMA in this setting
  • Adequately translate immunotherapy clinical trial findings into the real-world setting for patients with RRMM
  • Manage adverse events associated with the use of immunotherapy in the care of patients with RRMM

Faculty Disclosures

C. Ola Landgren, MD, PhD

Research Support

  • Amgen – clinical area: Myeloma
  • Janssen – clinical area: Myeloma
  • Celgene – clinical area: Myeloma
  • Takeda – clinical area: Myeloma

Honoraria

  • Amgen – clinical area: Myeloma
  • Janssen – clinical area: Myeloma
  • Celgene – clinical area: Myeloma

Independent Data Monitoring Committee

  • Takeda – clinical area: Myeloma
  • Janssen – clinical area: Myeloma

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is designated for up to 1.00 contact hour. Program ID# 5812-EM.
The Annenberg Center for Health Sciences is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.
A maximum of 1.00 contact hour may be earned for successful completion of this activity.
Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.00 contact hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.

Additional Content Planners

Maura Francesco, MD (Peer Reviewer)
No significant relationships to disclose.

Emir Hadzick, PhD (Medical Writer)
No significant relationships to disclose.

Heather M. Jimenez, FNP-C (Nurse Planner)
No significant relationships to disclose.

Annenberg Center for Health Sciences

All staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.